Generic Abilify Asimtufii Availability
Last updated on Apr 10, 2024.
See also: Generic Abilify
Abilify Asimtufii is a brand name of aripiprazole, approved by the FDA in the following formulation(s):
ABILIFY ASIMTUFII (aripiprazole - suspension, extended release;intramuscular)
-
Manufacturer: OTSUKA
Approval date: April 27, 2023
Strength(s): 720MG/2.4ML (300MG/ML) [RLD], 960MG/3.2ML (300MG/ML) [RLD]
Has a generic version of Abilify Asimtufii been approved?
No. There is currently no therapeutically equivalent version of Abilify Asimtufii available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify Asimtufii. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Injectable preparation
Patent 10,517,951
Issued: December 31, 2019
Inventor(s): Kaneko Daiki & Matsuda Takakuni & Hoshika Yusuke
Assignee(s): OTSUKA PHARMACEUTICAL CO., LTD.An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 sand having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s, as measured.
Patent expiration dates:
- April 23, 2033✓✓
- April 23, 2033✓✓
- April 23, 2033
-
Injectable preparation
Patent 11,097,007
Issued: August 24, 2021
Inventor(s): Kaneko Daiki & Matsuda Takakuni & Hoshika Yusuke
Assignee(s): OTSUKA PHARMACEUTICAL CO., LTD.An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 sand having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1,000 s, as measured.
Patent expiration dates:
- April 23, 2033✓✓
- April 23, 2033✓✓
- April 23, 2033
-
Patent 11,638,757
Patent expiration dates:
- April 23, 2033✓✓
- April 23, 2033✓✓
- April 23, 2033
-
Methods for administering aripiprazole
Patent 8,338,427
Issued: December 25, 2012
Inventor(s): Brown Josiah
Assignee(s): Alkermes, Inc.The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
Patent expiration dates:
- March 15, 2025✓✓
- March 15, 2025
-
Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Patent 8,399,469
Issued: March 19, 2013
Inventor(s): Bando Takuji & Aoki Satoshi & Kawasaki Junichi & Ishigami Makoto & Taniguchi Youichi & Yabuuchi Tsuyoshi & Fujimoto Kiyoshi & Nishioka Yoshihiro & Kobayashi Noriyuki & Fujimura Tsutomu & Takahashi Masanori & Abe Kaoru & Nakagawa Tomonori & Shinhama Koichi & Utsumi Naoto & Tominaga Mic
Assignee(s): Otsuka Pharmaceutical Co., Ltd.The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Patent expiration dates:
- June 29, 2025✓
- June 29, 2025
More about Abilify Asimtufii (aripiprazole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Breastfeeding
- En español
Patient resources
Other brands
Abilify, Abilify Maintena, Aristada, Aristada Initio, ... +2 more
Professional resources
Other brands
Abilify, Abilify Maintena, Aristada, Aristada Initio, Abilify MyCite
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.